Identification and characterization of autoantibodies against catalase and α‐enolase in patients with primary sclerosing cholangitis
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology. Recent studies have shown that genetic factors and both cellular and humoral immunological abnormalities are important in the pathogenesis of PSC. The most prominent autoantibodies in PSC are anti‐neutrophil cytoplasmic antibodies (ANCA). The autoepitopes of ANCA in PSC are not well defined. The aim of this study was to identify corresponding ANCA autoantigens in patients with PSC. A biochemical approach with enrichment and partial purification of soluble neutrophil proteins, detection of autoantibodies by Western blot and partial amino acid sequencing were used. Two new autoantigen/autoantibody systems in patients with PSC were detected: catalase and α‐enolase. The presence of catalase autoantibodies in 9/15 (60%) and α‐enolase autoantibodies in 4/15 (27%) was confirmed by ELISA and Western blot. Furthermore, we showed immunoreactions of PSC sera with human biliary epithelial cells, showed the reduction of fluorescence in anti‐catalase absorption experiments and observed partial co‐localization of anti‐catalase antibodies and PSC sera in double‐staining experiments on biliary epithelial cells. The anti‐catalase antibody‐positive PSC patients had a more severe course of disease with a significantly higher alkaline phosphatase compared with the anti‐catalase‐negative PSC patients (P < 0.06). All ulcerative colitis control sera were anti‐catalase antibody‐negative. The identified antigens catalase and α‐enolase can partly explain the ANCA fluorescence on ethanol‐fixed and formaldehyde‐fixed granulocytes in patients with PSC. Catalase is an important anti‐oxidant enzyme and prevents cell damage from highly reactive oxygen‐derived free radicals. Catalase autoantibodies might play a pathogenic role in patients with PSC. Our findings support the hypothesis that oxidative stress is one of the pathogenic mechanisms in patients with PSC.